PHAXIAM Therapeutics Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	31	4.18	3.72	5.28	4.45	3.36	4.14	2.93
Revenue Growth (YoY)	641.58%	12.43%	-29.62%	18.80%	32.19%	-18.70%	41.28%	-
Gross Profit	31	4.18	3.72	5.28	4.45	3.36	4.14	2.93
Selling, General & Admin	13.89	15.6	14.97	17.16	14.6	8.79	6.81	7.74
Research & Development	19.91	45.1	57.58	52.19	33.47	25.46	19.72	10.78
Operating Expenses	33.79	60.7	72.55	69.36	48.07	34.25	26.53	18.51
Operating Income	-2.8	-56.52	-68.83	-64.07	-43.62	-30.89	-22.39	-15.58
Interest Expense / Income	1.36	2.7	5.35	1.53	0.03	3.18	0.07	0.06
Other Expense / Income	-4.45	-5.42	-0.89	-2.95	-5.43	-0.54	-0.56	-0.63
Pretax Income	0.29	-53.8	-73.3	-62.66	-38.22	-33.53	-21.9	-15.02
Income Tax	0.52	0	0	-0	0	-0	0.01	-0
Net Income	-0.23	-53.8	-73.3	-62.66	-38.22	-33.53	-21.91	-15.01
Shares Outstanding (Basic)	3	3	2	2	2	2	2	-
Shares Change	17.32%	47.37%	-	0.01%	5.12%	-	-	-
EPS (Basic)	-0.10	-22.70	-39.90	-34.90	-21.30	-29.50	-27.40	-21.60
EPS (Diluted)	-0.10	-22.70	-39.90	-34.90	-21.30	-29.50	-27.40	-21.60
Free Cash Flow	5.78	-57.07	-52.78	-63.43	-53.49	-26.37	-19.37	-14.85
Free Cash Flow Per Share	1.86	-21.59	-29.42	-35.35	-29.82	-15.45	-11.35	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-9.02%	-1352.03%	-1851.32%	-1212.83%	-980.91%	-918.25%	-541.08%	-532.02%
Profit Margin	-0.74%	-1287.01%	-1971.49%	-1186.05%	-859.55%	-996.73%	-529.56%	-512.56%
Free Cash Flow Margin	18.65%	-1365.26%	-1419.47%	-1200.59%	-1202.88%	-783.77%	-467.98%	-506.90%
Effective Tax Rate	177.82%	-	-	-	-	-	-	-
EBITDA	6.28	-45.72	-62.95	-56.91	-37.4	-29.82	-21.41	-14.66
EBITDA Margin	20.25%	-1093.68%	-1693.17%	-1077.25%	-840.95%	-886.39%	-517.35%	-500.65%
Depreciation & Amortization	4.62	5.38	4.99	4.22	0.8	0.53	0.43	0.29
EBIT	1.66	-51.09	-67.94	-61.13	-38.19	-30.35	-21.83	-14.95
EBIT Margin	5.35%	-1222.32%	-1827.41%	-1157.05%	-858.87%	-902.20%	-527.62%	-510.48%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).